Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT GIST: Imatinib vs Alternating Imatinib/Regorafenib
NCT02365441Phase 2Unknown
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Jun 2015
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of regorafenib in gastrointestinal stromal tumor (GIST), sponsored by Australasian Gastro-Intestinal Trials Group. Status: unknown.
02
Drugs
regorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02365441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365441.